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Research
Phthalates are endocrine disruptors that have 
shown effects on reproductive health and 
development. Infertility, decreased sperm 
counts, cryptorchidism, reproductive tract 
malformations, hypospadias, and testicular 
tumors, as well as reduction on testosterone 
levels, anogenital distance, and reproductive 
organ weights and nipple retention, have been 
described both in animal and human studies 
(National Research Council 2008). Exposure 
to various phthalates in adult men has been 
associated with altered semen quality, reduced 
concentration of certain sexual and thyroid 
hormones, reduced pulmonary function, and 
increases in certain metabolic syndrome mark-
ers (Hauser and Calafat 2005; Swan 2008). In 
boys, prenatal exposure to some phthalates has 
been associated with a reduced anogenital dis-
tance (Swan et al. 2005). Exposure to phtha-
lates before birth has been related to gestational 
age, and exposure during childhood has been 
associated with respiratory problems, asthma, 
and allergies (Adibi et al. 2009; Hauser and 
Calafat 2005; Swan 2008; Wolff et al. 2008).
Several phthalates, such as diethyl phtha-
late (DEP) and dibutyl phthalate (DBP), are 
widely used, especially in cosmetic and per-
sonal care products for infants, children, and 
adults. Other phthalates, including diisobutyl 
phthalate (DiBP), butylbenzyl phthalate 
(BBzP), di(2-ethylhexyl) phthalate (DEHP), 
and di-n-octyl phthalate (DOP), can be used 
as plasticizers in the manufacture of flexible 
vinyl plastic in consumer products, flooring 
and wall coverings, food contact applications, 
and medical devices. Phthalates can also be 
used as solvents in combination with other 
plasticizers in floor coverings as well as in 
some cosmetics and pharmaceutical products 
(David and Gans 2003; Frederiksen et al. 
2007; Meeker et al. 2007).
Some phthalates can be absorbed through 
the skin (Janjua et al. 2007); in addition, they 
can be ingested, because they can migrate 
from wrappers and containers to foods 
(Wormuth et al. 2006). The metabolism of 
most phthalates in humans occurs first by 
hydrolysis of one ester bond to form the 
hydrolytic phthalate monoesters. Some phtha-
lates may undergo a phase I biotransformation 
in which oxidative metabolites are formed. 
Both monoester and oxidative metabolites 
may react with glucuronic acid in a phase II 
biotransformation to form their respective 
glucuronide conjugates. The phase II con-
jugation facilitates urinary excretion of the 
phthalate metabolites (Silva et al. 2003). 
The urinary concentrations of phthalate 
metabolites have been used extensively to 
assess exposure to phthalates in epidemiologic 
studies. The metabolism of phthalates was 
recently reviewed by Frederiksen et al. (2007) 
and the National Research Council (2008).
Women may be at a higher risk than 
men for potential adverse health effects of 
phthalates due to phthalate exposure through 
cosmetics use. However, potential effects of 
phthalate exposure have been documented pri-
marily in males. Health effects in women have 
been scarcely characterized, and studies have 
been limited to endometriosis (Cobellis et al. 
2003; Reddy et al. 2006a, 2006b) and thyroid 
hormone changes (Huang et al. 2007).
Breast cancer (BC) is hormone depen-
dent. Less than 25% of patients have a his-
tory of early menarche, later age at first 
childbirth, nulliparity, family history of BC, 
or history of benign breast biopsy (Rockhill 
et al. 1998); however, in most cases the 
causes of breast tumors are unknown, and 
environmental and genetic factors may play a 
role. The purpose of this study was to exam-
ine the association between exposure to six 
phthalates, estimated from urinary concen-
trations of nine selected phthalate metabo-
lites, and the risk of BC among a group of 
northern Mexican women.
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Ba c k g r o u n d: Phthalates, ubiquitous environmental pollutants that may disturb the endocrine 
system, are used primarily as plasticizers of polyvinyl chloride and as additives in consumer and 
personal care products.
oBjectives: In this study, we examined the association between urinary concentrations of nine 
phthalate metabolites and breast cancer (BC) in Mexican women.
Me t h o d s : We age-matched 233 BC cases to 221 women residing in northern Mexico. 
Sociodemographic and reproductive characteristics were obtained by direct interviews. Phthalates 
were determined in urine samples (collected pretreatment from the cases) by isotope dilution/high-
performance liquid chromatography coupled to tandem mass spectrometry.
re s u l t s: Phthalate metabolites were detected in at least 82% of women. The geometric mean 
concentrations of monoethyl phthalate (MEP) were higher in cases than in controls (169.58 vs. 
106.78 µg/g creatinine). Controls showed significantly higher concentrations of mono-n-butyl 
phthalate, mono(2-ethyl-5-oxohexyl) phthalate, and mono(3-carboxypropyl) phthalate (MCPP) 
than did the cases. After adjusting for risk factors and other phthalates, MEP urinary concentra-
tions were positively associated with BC [odds ratio (OR), highest vs. lowest tertile = 2.20; 95% 
confidence interval (CI), 1.33–3.63; p for trend < 0.01]. This association became stronger when 
estimated for premenopausal women (OR, highest vs. lowest tertile = 4.13; 95% CI, 1.60–10.70; 
p for trend < 0.01). In contrast, we observed significant negative associations for monobenzyl phtha-
late (MBzP) and MCPP.
co n c l u s i o n s: We show for the first time that exposure to diethyl phthalate, the parent compound 
of MEP, may be associated with increased risk of BC, whereas exposure to the parent phthalates of 
MBzP and MCPP might be negatively associated. These findings require confirmation.
key w o r d s : breast cancer, case–control study, endocrine disruptors, environment, Mexico, 
phthalates, risk assessment, urinary metabolites. Environ Health Perspect 118:539–544 
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Materials and Methods
Study population. From March 2007 to August 
2008 an epidemiologic population-based case–
control study was performed in the north-
ern states of Mexico (Baja California Norte, 
Chihuahua, Coahuila, Durango, Nuevo León, 
Sonora, and Tamaulipas). Cases were iden-
tified from 25 tertiary hospital units, which 
covered 90% of the study area population, 
including Health Department (Secretaría de 
Salud), Social Security (Instituto de Seguridad 
y Servicios Sociales), and State Workers’ Social 
Security (Instituto de Seguridad y Servicios 
Sociales de los Trabajadores del Estado) hos-
pitals, as well as university health centers. We 
identified 233 patients with histopathologi-
cally confirmed BC, with a minimal age of 18, 
without any other cancer history, and with a 
residency period of > 1 year in the study area 
(inclusion criteria).
The controls consisted of 221 healthy 
women that were matched 1:1 by age 
(± 5 years) and residency with the index case. 
Controls were identified through the mas-
ter sample framework used in the Health 
Department (Secretaría de Salud) national sur-
veys (Tapia-Conyer et al. 1992). A housing list 
representative of the study area was obtained, 
and it included an access sketch to facilitate 
the location of the probabilistically selected 
homes. In the cases where there was more than 
one eligible woman in a home, one partici-
pant was randomly chosen. Conversely, if no 
eligible woman was found in a household, or if 
she declined participation in the study, a new 
home was systematically located according to 
the survey procedures employed in other stud-
ies. This study was approved by the Mexico 
National Institute of Public Health ethical 
committee. The involvement of the Centers for 
Disease Control and Prevention (CDC) labo-
ratory was limited and determined not to con-
stitute engagement in human subjects research.
Interviews and urine samples. With their 
informed consent, women were directly inter-
viewed by personnel trained to carry out struc-
tured interviews. Information was obtained 
about sociodemographic characteristics; clini-
cal, reproductive (e.g., parity, lactation), and 
family medical history; dietary patterns; and 
anthropometric measures (e.g., weight, height). 
Patients were interviewed after their diagnosis, 
before any kind of treatment (average time 
from diagnosis ~ 2 months). Response rates 
(participants/eligible) were 94.8% for cases 
and 99.5% for controls.
A first morning void urine sample of each 
woman was collected in a sterile disposable 
polypropylene urine collection cup (polypro-
pylene plastics have not been reported to con-
tain detectable levels of phthalates). Among 
all cases, urine samples were obtained before 
any kind of treatment (including surgery and 
radiation therapy) was performed to exclude 
the possibility that phthalate exposure may 
have been influenced by cancer treatment. 
An aliquot of 4 mL of urine was prepared in 
a Cryovial (Simport Scientific, Beloeil, QC, 
Canada) and stored frozen at or below –20°C 
until shipment to the CDC. At the CDC, 
samples were kept frozen at –40°C until they 
were analyzed.
Assessment of phthalate metabolite urinary 
concentrations. The urinary concentrations of 
nine phthalate metabolites [monoethyl phtha-
late (MEP), mono-n-butyl phthalate (MBP), 
monoisobutyl phthalate (MiBP), mono  benzyl 
phthalate (MBzP), mono(3-carboxypropyl) 
phthalate (MCPP), and four metabolites of 
DEHP: mono(2-ethylhexyl) phthalate (MEHP), 
mono(2-ethyl-5-hydroxyhexyl) phthalate 
(MEHHP), mono(2-ethyl-5-oxohexyl) phtha-
late (MEOHP), and mono(2-ethyl-5-carboxy-
pentyl) phthalate (MECPP)] were measured in 
the analytical organic toxicology laboratory of 
the CDC according to methodology published 
elsewhere that includes solid-phase extrac-
tion coupled with high-performance liquid 
  chromatography/isotope dilution/tandem mass 
spectrometry (Kato et al. 2005).
Statistical analysis. First-hand confirma-
tion of the association of known BC risk fac-
tors was obtained through nonconditional 
logistic regression models. A linear trend 
between BC and parity, age at first birth, 
lactation, and body mass index was assessed 
by incorporating each factor as a continuous 
variable. Correlation coefficients were calcu-
lated between phthalates and BC risk factors 
among controls. Alpha level was set at 95%, 
and statistical significance was p < 0.05.
Phthalate metabolite urinary concen-
trations were adjusted for urine dilution by 
creatinine levels according to a previously 
detailed methodology (Barr et al. 2005) and 
transformed to a logarithmic scale. Phthalate 
metabolite concentrations below the limit of 
detection (LOD) were assigned a value equal 
to half the LOD (LOD/2) for the analysis. 
Correlations between metabolite concentra-
tions were estimated. The geometric means of 
these concentrations were compared between 
cases and controls with the Student t-test and 
stratified by menopausal status.
Tertiles of phthalate exposure were cre-
ated according to the observed distribution 
of urinary concentrations of the metabolites 
in the controls. To evaluate their potential 
association to BC, two multivariate logistic 
models were run for each phthalate metabo-
lite. One model was adjusted for age, and 
the variables that were significantly correlated 
with any of the phthalate metabolite concen-
trations among controls: age of menarche, 
parity, and menopause. The second model for 
MEP, MBP, MiBP, MBzP, and MCPP was 
adjusted for the previous variables and the 
sum of DEHP metabolites; similarly, the sec-
ond model for DEHP was adjusted for MEP, 
MBP, MiBP, MBzP, and MCPP. The models 
that reached the statistical level of significance 
were further stratified by menopausal status. 
Median values were assigned to phthalate 
metabolite concentrations tertiles, and they 
were modeled as continuous variables to esti-
mate trend p-values. Active smoking did not 
change the results, and it was not included in 
the final models. Data analysis was performed 
using the Stata version 9 statistical software 
(StataCorp, College Station, TX, USA).
Results
By design, the mean age (years) of the study 
population was similar in both groups: 53.41 
± 12.78 in cases and 53.83 ± 12.54 in con-
trols (data not shown). The known BC factors 
associated with a reduction (higher parity and 
lactation) and with an increased risk (early 
menarche, older age at first childbirth, and 
higher body mass index after menopause) 
were confirmed in this population (Table 1). 
Family history of BC was absent among con-
trols and is not included in Table 1.
We found significant negative correla-
tions between age at menarche and the urinary 
concentrations of MBP and MiBP among 
controls. In contrast, current age and parity 
showed significant positive correlations with 
the urinary concentrations of MEHHP and 
MECPP, respectively, as well as parity with 
MEOHP. We detected no other significant 
Table 1. Age-adjusted ORs for known BC risk 
  factors.
Factor
Cases/controls 
(n = 233/221) OR (95% CI)
Age of menarche (years)
> 12 129/145 1.00
≤ 12 103/76 1.52 (1.03–2.23)
Parity (no.)
Nulliparous 20/8 1.00
1–3 91/73 0.52 (0.22–1.26)
4–6 74/71 0.41 (0.17–0.99)
> 6 47/69 0.23 (0.09–0.60)*
Age at first birth (years)
< 19 52/79 1.00
19–21 62/64 1.47 (0.90–2.41)
≥ 22 99/70 2.15 (1.35–3.42)
Nulliparous 20/8 3.77 (1.55–9.21)*
Lactation
No 70/26 1.00
< 1 year 91/78 0.44 (0.25–0.76)
≥ 1 year 68/117 0.21 (0.12–0.36)*
Body mass index
Premenopause
< 25 28/24 1.00
25–29.99 35/23 1.33 (0.62–2.84)
≥ 30 25/27 0.83 (0.38–1.81)
Postmenopause
< 25 14/36 1.00
25–29.99 57/47 3.25 (1.56–6.78)
≥ 30 74/64 3.14 (1.55–6.40)**
Some numbers do not equal the total sample size because 
of missing values.
*p-Value for trend < 0.05. **p-Value for trend = 0.056. Phthalates and breast cancer risk in Mexico
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correlations between phthalate metabolite 
concentrations and BC risk factors among 
controls (Table 2).
All samples had detectable concentrations 
of MEP, MBP, MEHHP, MEOHP, and 
MECPP. Concentrations were most likely to 
be undetectable for MEHP (82% of samples). 
MEP geometric mean concentrations were 
significantly higher in cases than in controls. 
Conversely, controls had significantly higher 
geometric mean MBP, MCPP, and MEOHP 
levels than did cases. Similar patterns were 
observed after stratifying by menopausal status 
(Table 3). Significant (p < 0.05) correlation 
coefficients (> 0.6) were observed among the 
DEHP metabolites as well as between MCPP 
[a minor metabolite of DBP and of other 
phthalates (Calafat et al. 2006)] and MBP (the 
major metabolite of DBP); other metabolites 
showed lower correlations [see Supplemental 
Material (doi:10.1289/ehp.0901091)].
MEP urinary concentrations were signifi-
cantly associated with BC, with a significant 
test for lineal trend. In contrast, significant 
negative associations were observed with MiBP, 
MBzP, and MCPP. Neither the sum of DEHP 
metabolites nor the specific DEHP metabolite 
concentrations showed an association with BC, 
except for MECPP, which showed borderline 
significance after adjusting for reproductive 
covariates and other phthalates (Table 4).
When stratified by menopausal status, the 
increased BC risk observed for the highest 
versus lowest tertile of MEP was significantly 
higher only in premenopausal women, and 
the association remained when adjusted for 
other phthalate metabolites [odds ratio (OR) 
= 4.13; 95% confidence interval (CI), 1.60–
10.70; p for trend < 0.004]; this was also the 
case for the negative associations with BC 
observed for the highest versus lowest tertile 
of MBzP (OR = 0.22; 95% CI, 0.08–0.61; 
p for trend < 0.006) and for the highest versus 
lowest tertile of MCPP (OR = 0.18; 95% CI, 
0.05–0.59; p for trend < 0.003) (Table 5).
Discussion
This study suggests for the first time that uri-
nary concentrations of some phthalate metab-
olites may be related to BC independent of 
other known risk factors: MEP, the main 
DEP metabolite, is significantly associated 
with incident BC in premenopausal women, 
and the metabolites of BBzP (MBzP) and 
of DOP and other phthalates (MCPP) are 
inversely associated with BC.
Two recent epidemiologic reports involv-
ing men attending an infertility clinic showed 
that sperm DNA damage was associated with 
urinary concentrations of MEP but not of 
MBP or MBzP (Duty et al. 2003; Hauser 
et al. 2007). Other phthalates and/or their 
metabolites have been reported to damage 
DNA, as assessed by the alkaline comet assay 
(single-cell gel electrophoresis). DNA damage 
was detected in human lymphocytes exposed 
to DEHP and MEHP (Anderson et al. 1999). 
Also, DBP and DiBP were shown to be geno-
toxic in human epithelial cells of the upper 
aerodigestive tract, mucosal cells, and lympho-
cytes (Kleinsasser et al. 2000). These studies 
suggest that MEP and other phthalates have 
the potential to induce DNA damage and 
increase cancer risk; however, further research 
is needed to fully characterize the genotoxic 
effects of phthalates on human breast cells.
The epigenetic effects of phthalates, such 
as DNA methylation, might explain the neg-
ative associations of MBP and MBzP with 
BC observed in this study. BBzP and DBP, 
parent compounds of MBzP and MBP, 
respectively (MBP is also a minor metabo-
lite of BBzP), led to demethylation of estro-
gen receptor α promoter–associated CpG 
islands, producing a growth inhibitory effect 
on human MCF-7 BC cells (Kang and Lee 
2005), thus reducing BC risk.
Table 2. Correlation coefficients between BC covariates and urinary phthalate metabolites (µg/g creatinine) among controls (n = 221).
Phthalates (parent/metabolite)
Breast cancer covariate
DEP/
MEP
DBP/
MBP
DiBP/
MiBP
BBzP/
MBzP
DOPa/
MCPP
DEHP/
MEHP
DEHP/
MEHHP
DEHP/
MEOHP
DEHP/
MECPP
Age (years) –0.03 –0.02 –0.12 –0.07 0.06 0.07 0.18* 0.11 0.16*
Age at menarche (years) 0.05 –0.22* –0.13* –0.05 –0.13 –0.10 –0.01 –0.01 –0.03
Parity (number) –0.05 0.01 0.02 –0.01 0.07 0.02 0.20* 0.17* 0.18*
Age at first birth (years) –0.12 –0.08 –0.07 –0.01 0.01 0.11 0.06 0.04 0.04
Body mass index (kg/m2) –0.01 0.02 0.02 –0.05 –0.08 –0.07 0.05 –0.02 0.03
aIncludes other phthalates. *p < 0.05.
Table 3. Urinary phthalate metabolites (µg/g creatinine) in the study population by menopausal status [geometric mean (95% CI)].
All Premenopause Postmenopause
Parent compound/metabolite Cases (n = 233) Controls (n = 221) p-Value Cases (n = 88) Controls (n = 74) p-Value Cases (n = 145) Controls (n = 174) p-Value
DEP/MEP 169.58 
(141.92–202.64)
106.78 
(91.25–124.96)
 
< 0.001
184.77 
(138.93–245.73)
111.69 
(84.53–147.57)
0.007 160.98 
(127.88–202.63)
104.40 
(86.11–126.56)
0.002
DBP/MBP 62.98 
(56.06–70.76)
82.47 
(72.67–93.60)
0.001 57.56 
(47.63–69.55)
81.61 
(65.61–101.51)
0.008 66.52 
(57.33–77.18)
82.91 
(70.85–97.03)
0.023
DiBP/MiBP 7.81 
(6.93–8.81)
8.85  
(7.95–9.84)
0.065 8.31 
(6.85–10.09)
9.99 
(8.42–11.85)
0.084 7.53 
(6.45–8.78)
8.32  
(7.27–9.52)
0.167
BBzP/MBzP 5.43 
(4.81–6.13)
6.27 
 (5.38–7.31)
0.072 5.29 
(4.42–6.34)
7.22  
(5.67–9.20)
0.020 5.51 
(4.68–6.49)
5.84  
(4.80–7.10)
0.327
DOP and other phthalates/
MCPP
2.68 
(2.43–2.95)
4.07  
(3.66–4.54)
< 0.001 2.57 
(2.23–2.95)
3.92  
(3.22–4.78)
< 0.001 2.75 
(2.41–3.14)
4.15  
(3.64–4.73)
< 0.001
DEHP/MEHP 5.13 
(4.45–5.90)
5.09  
(4.47–5.78)
0.467 6.13 
(4.95–7.60)
5.42  
(4.25–6.91)
0.224 4.60 
(3.82–5.53)
4.93  
(4.23–5.73)
0.285
DEHP/MEHHP 49.10 
(43.65–55.23)
48.71 
(44.10–53.81)
0.460 45.00 
(37.05–54.66)
41.22 
(33.81–50.24)
0.266 51.76 
(44.60–60.07)
52.99 
(47.44–59.19)
0.401
DEHP/MEOHP 28.11 
(25.01–31.59)
33.37 
(30.29–36.77)
0.014 27.47 
(22.8–33.10)
30.15 
(24.98–36.40)
0.244 28.50 
(24.50–33.15)
35.12 
(31.41–39.26)
0.014
DEHP/MECPP 87.10 
(78.37–96.80)
79.16 
(72.06–86.97)
0.093 82.74 
(69.35–98.72)
70.09 
(58.39–84.14)
0.099 89.85 
(78.66–102.63)
84.17 
(75.58–93.73)
0.225
Sum of metabolites 174.35 
(156.58–194.15)
169.69 
(154.60–186.26)
0.355 165.65 
(138.65–197.91)
149.82 
(124.7–180.01)
0.219 179.86 
(156.94–206.12)
180.67 
(162.60–200.76)
0.479
Percentage of samples below LOD: among cases, 0% for MEP, MBP, MEHHP, MEOHP, and MECPP, 3% for MiBP, 2% for MBzP, 3% for MCPP, and 18% for MEHP; among controls, 0% 
for MEP, MBP, MEHHP, MEOHP, and MECPP, 3% for MiBP, 10% for MBzP, 2% for MCPP, and 17% for MEHP.López-Carrillo et al.
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Another potential underlying mechanism 
to explain the mentioned negative associa-
tions is related to the effects of phthalates on 
peroxisome proliferator–activated recep-
tors (PPARs) and the key role these ligand-
  activated transcription factors have in the 
proliferation and differentiation of BC cell 
lines and in breast development. PPARγ is 
associated with differentiation, increased lipid 
accumulation, and inhibition of BC cell pro-
liferation (Elstner et al. 1998; Mueller et al. 
1998), and available evidence shows that 
DBP/MBP and BBzP/MBzP have moderate 
but consistent associations with PPARγ acti-
vation (Bility et al. 2004; Feige et al. 2007; 
Hurst and Waxman 2003). In this context, 
further information is needed to explain 
the negative association found in this study 
regarding MCPP, a nonspecific metabolite of 
several phthalates, including DOP and DBP 
(Calafat et al. 2006), and BC.
Regarding DEHP metabolites, we found 
no association with BC in this study. These 
findings may result from the opposing effects 
that individual phthalates and/or metabo-
lites could have. For example, MEHP acti-
vated both human PPARα and PPARγ but 
not PPARβ; the former PPARs have oppos-
ing functions in the breast epithelial cell line 
MCF-7, so the net effect of DEHP exposure 
would result from a complex series of compet-
itive underlying mechanisms. In this context, 
MBP acted as an antagonist for both PPARγ 
and PPARβ (Venkata et al. 2006). Studies 
summarizing the effects of each parent phtha-
late and each metabolite, whether they are 
estrogenic or androgenic, and whether they 
activate or inhibit the various PPARs have 
been published (Corton and Lapinskas 2005; 
Hatch et al. 2008).
Deodorants, fragrances, creams, and nail 
polishes, among other personal care prod-
ucts, may contain phthalates, including DEP, 
the parent compound of MEP, as well as 
DBP and BBzP, the parent compounds of 
MBP and MBzP, respectively (Chingin et al. 
2009; Cosmetic Ingredient Review 2003; 
Health Care without Harm 2002; Houlihan 
et al. 2002; Koo and Lee 2004; Scientific 
Committee on Cosmetic Products and Non-
food Products 2002). DEP has been found 
in a high proportion (28–71%) of the per-
sonal care products, 57–72% of perfumes, 
and 25% of deodorants tested in some studies. 
DBP was detected in 24–75% of personal 
care products, 26% of perfumes, and 67–90% 
of the nail polishes, and DOP (parent com-
pound of MCPP) was detected in 21% of 
deodorants. In contrast, BBzP and DEHP 
were not detected in most deodorants and 
hair products and in less than one-third of 
all products (Chingin et al. 2009; Health 
Care without Harm 2002; Houlihan et al. 
2002; Koo and Lee 2004). DEP, DBP, DiBP, 
DEHP, and BBzP have also been detected in 
foods (Wormuth et al. 2006), and DBP has 
been found in water from plastic bottles (Cao 
2008). Some of these phthalates are used in 
the production of enteric coatings for drugs 
(Hauser and Calafat 2005).
The main route of exposure to DEP is der-
mal (Agency for Toxic Substances and Disease 
Registry 1995; Api 2001; Mint et al. 1994; 
Scott et al. 1987). The application of a cream 
containing DEP and DBP on the entire body 
enabled detection of their main metabolites in 
urine, indicating a fast and regular absorption 
through the skin (Janjua et al. 2007, 2008). 
In addition, a steep relationship between uri-
nary MEP levels and the reported use of per-
sonal care products in the 48 hr before urine 
collection was observed in a group of men 
in the United States (Duty et al. 2005), and 
increasing urinary concentrations with the use 
of DEP-containing products, without statis-
tical dose–response relationship, have been 
recently observed in a small group of Israeli 
women (Berman et al. 2009).
Table 4. Adjusted ORs for urinary phthalate metabolites and BC.
OR (95% CI)
Phthalate tertile  
(µg/g creatinine)
Median in 
controls
Cases/ 
controls
Adjusted for BC 
covariatesa
Adjusted for BC covariates 
and phthalate metabolitesb
DEP/MEP
9.40–56.18 32.79 56/74 1.00 1.00
56.19–181.35 99.76 72/74 1.26 (0.77–2.05) 1.42 (0.85–2.38)
181.36–18985.50 386.75 103/73 1.94 (1.21–3.12) 2.20 (1.33–3.63)
p-Value for trend 0.005 0.003
DBP/MBP
6.21–52.55 35.84 97/74 1.00 1.00
52.55–113.69 72.62 87/74 0.89 (0.57–1.38) 1.08 (0.66–1.78)
113.70–1746.03 179.30 47/73 0.46 (0.28–0.76) 0.85 (0.47–1.57)
p-Value for trend 0.001 0.511
DiBP/MiBP
0.23–7.44 4.90 105/74 1.00 1.00
7.45–12.07 9.55 60/74 0.61 (0.38–0.97) 0.59 (0.35–0.98)
12.08–86.22 17.40 66/73 0.68 (0.43–1.07) 0.73 (0.43–1.24)
p-Value for trend 0.125 0.365
BBzP/MBzP
0–5.18 2.85 113/74 1.00 1.00
5.19–10.79 7.23 68/74 0.59 (0.38–0.93) 0.60 (0.37–0.98)
10.80–258.62 16.45 50/73 0.46 (0.29–0.74) 0.46 (0.27–0.79)
p-Value for trend 0.002 0.008
DOP and other phthalates/MCPP 
0.22–2.83 2.04 119/74 1.00 1.00
2.84–5.28 3.73 72/74 0.69 (0.44–1.07) 0.76 (0.47–1.23)
5.29 –193.91 8.25 40/73 0.35 (0.21–0.57) 0.44 (0.24–0.80)
p-Value for trend  < 0.001 0.007
DEHP/MEHP
0.22–3.42 2.06 81/74 1.00 1.00
3.43–7.51 5.33 67/74 0.85 (0.53–1.36) 1.03 (0.62–1.69)
7.52–257.08 12.28 83/73 0.99 (0.63–1.57) 1.23 (0.75–2.01)
p-Value for trend 0.904 0.383
DEHP/MEHHP
2.69–35.61 24.93 90/74 1.00 1.00
35.62–63.38 47.47 53/74 0.61 (0.38–0.99) 0.77 (0.46–1.28)
63.39–1014.60 95.58 88/73 1.01 (0.64–1.58) 1.37 (0.84–2.24)
p-Value for trend 0.650 0.106
DEHP/MEOHP
2.10–23.90 17.39 108/74 1.00 1.00
24.91–43.10 32.95 51/74 0.49 (0.31–0.79) 0.60 (0.36–1.00)
43.11–1230.94 64.62 72/73 0.66 (0.42–1.04) 0.84 (0.52–1.36)
p-Value for trend 0.130 0.651
DEHP/MECPP
11.59–57.88 42.02 69/74 1.00 1.00
57.89–97.67 74.56 73/74 1.04 (0.65–1.67) 1.27 (0.77–2.10)
97.68–1742.92 155.88 89/73 1.31 (0.82–2.08) 1.68 (1.01–2.78)
p-Value for trend 0.222 0.047
Sum of metabolites
18.56–120.79 88.09 82/74 1.00 1.00
120.80–207.46 161.62 62/74 0.79 (0.49–1.27) 0.94 (0.57–1.56)
207.47–4,193.90 317.41 87/73 1.09 (0.69–1.71) 1.41 (0.86–2.31)
p-Value for trend 0.539 0.114
aAdjusted for current age, age of menarche, parity, and menopausal status. bAdjusted for current age, age of menarche, 
parity, and menopausal status plus phthalate metabolites: DEHP metabolites were adjusted for non-DEHP metabolites; 
MEP, MBP, MiBP, BBzP, and MCPP were adjusted for themselves plus the sum of DEHP metabolites.Phthalates and breast cancer risk in Mexico
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Differences in the phthalate metabolite 
profiles among women from various coun-
tries have been observed (Berman et al. 2009; 
Hogberg et al. 2008; Huang et al. 2007). 
For the present study, the urinary concentra-
tions of MBP, MiBP, MEHP, MEHHP, and 
MEOHP found in the cases and controls were 
higher than those reported for females in the 
general U.S. population from the 2001–2002 
National Health and Nutrition Examination 
Survey (MBP = 21.7, MiBP = 2.87, MEHP 
= 4.53, MEHHP = 19.7 µg/g creatinine) and 
other specific groups of U.S. women (Adibi 
et al. 2008; CDC 2005; Hines et al. 2009; 
Peck et al. 2010; Swan et al. 2005; Wolff et al. 
2008). Currently, limited information is avail-
able regarding the presence of phthalates in 
personal care and other products (e.g., drugs) 
to estimate their relative contribution to the 
total body burden of phthalates.
As for the methodological strengths of 
our project, > 90% of BC incident cases dur-
ing the study period in the study area were 
included, as well as a representative sample 
of healthy women drawn from the popula-
tion in which the cases occurred, which adds 
external validity to the study. This is sup-
ported by the confirmation of the presence 
of known BC factors (e.g., lactation, parity) 
in this population (World Cancer Research 
Fund/American Institute for Cancer Research 
2007). Also, the very high rates of participa-
tion reduced the possibility that different char-
acteristics (potential or observed) among the 
very few nonparticipants versus participants 
might have influenced results. The possibility 
of a differential measurement error is very low 
because phthalate exposure was evaluated in 
biological samples and so did not depend on 
women’s reports, and the laboratory assess-
ment was blind in relation to case/control 
status. Moreover, urine samples for phtha-
late determination were obtained in all cases 
before treatment began, so it is unlikely that 
phthalate exposure in cases was influenced by 
cancer treatment. However, further informa-
tion is needed regarding disease status that 
might be reflected in changes of phthalate 
metabolite concentrations.
Our study also has several potential limi-
tations. Although urinary concentrations of 
phthalate metabolites are the most common 
strategy for assessing human exposure to 
phthalates and are an integral measurement of 
exposure through multiple sources and routes, 
an important limitation of this study relates 
to the fact that a single measurement does 
not allow evaluation of cumulative exposure 
or exposure windows. Therefore, the assump-
tion underlying our interpretation is that the 
urinary phthalate concentrations observed in 
these women predict their steady-state concen-
trations, if we consider that the use of personal 
care products may be fairly constant over time. 
However, further studies are needed to char-
acterize the magnitude and profile of exposure 
in order to obtain a more valid predictive bio-
marker of phthalate exposure. Also, because of 
the small sample size involving stratification of 
pre- and postmenopausal women, additional 
studies are needed to assess potential differ-
ences of the associations between phthalate 
exposure and BC by menopausal status.
Conclusions
Our results show for the first time that expo-
sure to DEP, as assessed by urinary MEP con-
centrations, may be associated with an increase 
in BC risk, whereas the exposure to other 
phthalates, measured by the urinary concentra-
tions of MBzP (BBzP) and MCPP (DOP and 
other phthalates), were negatively associated 
with BC. The findings require confirmation 
to exclude the possibility that these parent/ 
metabolite phthalates are surrogates of unrecog-
nized lifestyle or dietary BC risk factors.
The various sources and levels of exposure 
to relevant phthalates present in cosmetics and 
other personal care products deserve further 
assessment, particularly at critical windows of 
exposure, such as adolescence. Also, the bio-
logical mechanisms warrant clarification.
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